chrisvoncsefalvay/vaers-outcomes huggingface dataset:
sweat; aches in her whole body; a very ugly thing on her head, a discomfort on her head; low grade fever; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (sweat), MYALGIA (aches in her whole body), HEAD DISCOMFORT (a very ugly thing on her head, a discomfort on her head) and PYREXIA (low grade fever) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by reporter.  Concomitant products included INSULIN, METFORMIN and VITAMINS NOS for an unknown indication.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, the patient experienced HYPERHIDROSIS (sweat), MYALGIA (aches in her whole body), HEAD DISCOMFORT (a very ugly thing on her head, a discomfort on her head) and PYREXIA (low grade fever). At the time of the report, HYPERHIDROSIS (sweat), MYALGIA (aches in her whole body), HEAD DISCOMFORT (a very ugly thing on her head, a discomfort on her head) and PYREXIA (low grade fever) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment and concomitant medications were not provided by reporter.
Discharge Provider: Private, DO Primary Care Provider : Private, MD (Inactive) None Admission Date: 7/28/2022 Discharge Date: 07/29/2022 Admitting Diagnoses: Active Problems: COVID-19 virus detected. PRESENTING PROBLEM: Delirium HOSPITAL COURSE: Patient is a 71 y.o. female with dementia who presented to the emergency department with lethargy, cough and low-grade fever. Tested positive for COVID-19 B PCR in the emergency room. CXR showed no acute airspace process. Emergency room requested admission for increased lethargy. She never required any supplemental oxygen during hospitalization. Evaluated by PT recommended home with assist; care management and not with husband and offered home health therapies that were declined by the husband. Husband in agreement with discharge home on 07/29 given patient mental status back to baseline and lethargy improved.
pt recv vax 22FEB96 & on the morning of 1MAR devel a fever of 102;mom reported pt had a sz w/eyes rolling back in head & arms & legs jerking;pt was taken to local ER for eval;MD felt that pt was having a rxn to MMR vax;rash devel 2MAR
My symptom began with an itchy spot on my left forearm advancing to the back of my neck and head followed by a rash. The rash extended over my neck, chest, face, spreading to entire body. The left side of my lip also had swollen and became tingly. All symptoms started roughly at 3am on 3/4/21. I took ibuprofen 800mg along with Benadryl 25mg. At 0730am rash had dissipated some and most of the itching subsided, another Benadryl 25mg tablet was taken. At 1030am, rash had dissipated except still remaining on both elbow areas, non itching at this point. At 1230, another Benadryl was taken.
She began with high fevers (102.9F). Fevers lasted approx 4 days during which time she had a runny nose, cough, red/irritated eyes, she was lethargic. Then when the fever began to subside she started with the rash. The rash was severe and lasted 3 days.
not receiving 2nd dose on time; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (not receiving 2nd dose on time) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031h21a and 013f21a) for COVID-19 vaccination.     No Medical History information was reported.   On 21-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 ml. On 03-Jan-2022, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 ml. On 03-Jan-2022, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (not receiving 2nd dose on time). On 03-Jan-2022, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (not receiving 2nd dose on time) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.    This case was linked to MOD-2022-440055 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 04-Jan-2022: No new information received
Acute systolic CHF (congestive heart failure) 5/19/22 COVID-19 virus detected 5/19/22
No adverse effects.  Received the Tdap vaccination and current age is 69 years.
RASH TO BOTH ARMS AND REST OF THE  BODY; BUMPS TO BODY AND HIVES; This spontaneous report received from a patient concerned a 41 year old female. The patient's weight, height, and medical history were not reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported and batch number: 042A21A expiry: UNKNOWN) dose was not reported, administered on 31-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 05-APR-2021, the subject experienced rash to both arms and rest of the body. On 05-APR-2021, the subject experienced bumps to body and hives. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from rash to both arms and rest of the body, and bumps to body and hives. This report was non-serious.
For the first day of the 2nd shot I didn't feel anything harmful. on the second day I had fatigue, body aches, and I started noticing my body was itching. On the third day I had a rash forming and on the forth day it was all over my chest back stomach and thighs.
1. Near immediate severe cramping of legs, persisting 3-4 weeks 2. Frequent, severe and sometimes explosive diarrhea, associated with abdominal cramping. Incapacitating.  Lasted approximately 6 weeks.  3. At least two episodes of encephalopathy manifest by stupor and memory loss.  Each episode lasting 2-3 days.
fx femur lt 8AUG-recovered to walking w/cane & no pain; awoke morning p/flu shot w/sharp pain in leg radiating to knee; needing to use walker now due to pain;
RECTAL BLEEDING; LOSS OF APPETITE; ABDOMINAL PAIN; BODY ACHES; FEVER; INJECTION SITE SORENESS; This spontaneous report received from a consumer concerned an 18 year old female. The patient's height, and weight were not reported. The patient was not pregnant at the time of reporting and had no medical history. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported) dose was not reported, 1 total administered on 28-JUN-2021 early afternoon to left arm for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 28-JUN-2021, the patient experienced injection site soreness. On 29-JUN-2021, the patient experienced loss of appetite (good 12 hours without eating), abdominal pain, body aches, and fever. The patient also experienced rectal bleeding which started in the afternoon and described as bleeding every time she went; it was like having period but it was not. The patient bled pretty good amount. The patient recovered from loss of appetite and was able to eat dinner. The reporter stated that the patient was feeling pretty good except for the bleeding and that the patient had not had any treatment and had not notified the health care provider. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from loss of appetite on 29-JUN-2021, and abdominal pain, and fever on JUN-2021, was recovering from body aches, and had not recovered from injection site soreness, and rectal bleeding. This report was serious (Other Medically Important Condition).; Sender's Comments: V0-20210668208-Covid-19 vaccine ad26.cov2.s - RECTAL BLEEDING . This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
came down with the covid virus; came down with the covid virus; This is a spontaneous report received from a contactable consumer (patient). This 66-year-old-male patient reported that he received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration on 25Jan2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced came down with the covid virus about 2 weeks after the vaccine in Feb2021 with outcome of unknown. MD told patient he should wait 90 days before getting the 2nd shot.   Information about batch/lot number has been requested.
PATIENT REPORTS WAKING UP THE NEXT MORNING WITH MIGRAINE, FULL BODY ACHES, CHILLS, NAUSEA WHICH LASTED FOR 12 HOURS PRIOR TO FEELING BETTER.  PATIENT BELIEVES THAT THIS WAS FROM THE RSV AND NOT BOOSTRIX SINCE ALL HER SYMPTOMS WERE SAME AS THOSE LISTED FOR RSV.  PATIENT DID NOT TAKE ANY MEDICATIONS FOR SYMPTOM CONTROL.  ALSO, ITCHING AND WARM TO TOUCH AT THE INJECTION SITE WITH STARTED ON MONDAY (3 DAYS) AFTER RSV AND RESOLVED ON IT'S OWN IN 5 DAYS.
Atrial fibrillation onset at 8 PM converting to sinus rhythm at 11 PM.
Some redness the night of 7/21/16. Low grade fevers, site warm to touch. On clindamycin oral.
(5) minutes post immunization developed (L) arm weakness with pin/needles sensation down (L) arm, decreased ROM. Became flushed/ x 15 minutes, lasted until next am, slowly resolving. No rash, H/A, blurred vision. No N/V/D. Seen in hospital 10/4 - symptoms resolving, good grip, F.R.O.M.
Patient is being treated at this time. Child received vaccines 4 days ago. Developed fever 101-1-4 3 days ago. Has also developed area of erythema and induration over place of injection that is getting worse.
Case number PHEH2015US020301 is an initial spontaneous report received from a nurse on 08 Oct 2015. This report refers to a 55 year old male patient. Past medical history and concomitant medications were not reported. He was vaccinated with FLUVIRIN (batch number: 1515701) at a dose of 0.5 ml intramuscularly on 07 Oct 2015. The nurse reported that the patient was administered FLUVIRIN multi dose vial (MDV) that was in out of temperature range at 47 degree Fahrenheit. No adverse events were reported following the maladministration.
24 hours after vaccination developed swollen, red left deltoid, warm to touch. 48 hours after more swollen. Rx Benadryl/Keflex.
Started with body aches, then the chills came. Had a fever of 102 F. Worst headache ever. Tylenol/ibuprofen did not help with the fever or pain. Exhaustion.  Also did not get my period that month. symptoms lasted for 3 days.
Booster administered to 17 year old. No adverse reaction noted.  Patient & mother aware.
Fully vaccinated with Pfizer-BioNTech vaccine. Was exposed to COVID-19 by family members, COVID-19 positive tests for family members were on 4/19 and 4/20.  His positive test was on 4/21/2021.  He was asymptomatic.  He was tested as part of routine testing done at the Correctional Facility.  He remains symptom free at this time.
First dose:  Fatigue for 48 hours after Period came early by over a week Light period spotting constantly since  Second dose:  First 48 hours: Arm pain, fever, fatigue, chills Period spotting has continued, very light, but constant, even 2 weeks post second dose.  Spotting has lasted near 6 weeks now. No spotting before vaccine was normal for me. Never had it before.
Local rxn (swelling) at injection site immediately. Within 5 min pt noticed tingling sensation through chest area and other arm.
Positive Binax antigen test for COVID.  Taking Paxlovid beginning evening of June 29, 2022.  No symptoms
I had a low grade fever for about 4 hours, but as the fever was subsiding, I felt nauseous and I fainted. After fainting I didn't feel nauseated and my fever was gone. I would estimate that I was unconscious for 30 seconds to 1 minute before my husband found me and woke me.
HPV9 given to 1 year old pt. suppose to receive PCV13. Spoke to parent no reaction to vaccine.
Patient's first day of last menstrual period was 3/23/2021.  Patient has a predictable monthly cycle with an average length of 30 days.  Patient reports two positive at home urine pregnancy tests on 4/30/21 and 5/1/21.  Conception likely occurred on or around 4/6/21.  Patient reports vaginal bleeding that started on 5/14/21.  Patient had transvaginal ultrasound on 5/17/21.  Impression: FIRST TRIMESTER ULTRASOUND, SINGLETON An early intrauterine singleton pregnancy is visualized. A fetal pole is visualized but fetal cardiac activity is NOT present. The fetal biometry is appropriate for gestational age. Anatomic survey is precluded by early gestational age. As the CRL <7mm (measures 2.6mm) a definitive diagnosis of a missed miscarriage can not be made I would recommend a follow up ultrasound in 10-14d.  Follow up ultrasound on 5/27/21 could not visualize pregnancy.  Impression: The endometrium measures 14.39 mm, with heterogenous echotexture suggestive of retained products. The right and left ovaries appear normal.
Joint inflammation, ankles, knees, and wrist inflammation, and was diagnosed with rheumatoid arthritis; 3 weeks later he started to have back and knee pain; 4 weeks after the vaccine, was when inflammation started to get severe/joint inflammation, ankles, knees, and wrist inflammation, and was diagnosed with rheumatoid arthritis; By 8 weeks, he could barely walk due to the pain from inflammation; 3 weeks later he started to have back and knee pain; This spontaneous case was reported by a consumer and describes the occurrence of RHEUMATOID ARTHRITIS (Joint inflammation, ankles, knees, and wrist inflammation, and was diagnosed with rheumatoid arthritis) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   In May 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced RHEUMATOID ARTHRITIS (Joint inflammation, ankles, knees, and wrist inflammation, and was diagnosed with rheumatoid arthritis) (seriousness criterion medically significant), BACK PAIN (3 weeks later he started to have back and knee pain), INFLAMMATION (4 weeks after the vaccine, was when inflammation started to get severe/joint inflammation, ankles, knees, and wrist inflammation, and was diagnosed with rheumatoid arthritis), HYPOKINESIA (By 8 weeks, he could barely walk due to the pain from inflammation) and ARTHRALGIA (3 weeks later he started to have back and knee pain). At the time of the report, RHEUMATOID ARTHRITIS (Joint inflammation, ankles, knees, and wrist inflammation, and was diagnosed with rheumatoid arthritis), BACK PAIN (3 weeks later he started to have back and knee pain), INFLAMMATION (4 weeks after the vaccine, was when inflammation started to get severe/joint inflammation, ankles, knees, and wrist inflammation, and was diagnosed with rheumatoid arthritis), HYPOKINESIA (By 8 weeks, he could barely walk due to the pain from inflammation) and ARTHRALGIA (3 weeks later he started to have back and knee pain) outcome was unknown.            Concomitant product was not provided by the reporter Lab data was not provided Treatment product was not provided by the reporter  Company comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   This case was linked to MOD-2021-294210 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Redness & swelling of lt thigh on 10AUg91 PM; Taken to ER w/rx of Cephalexin & DPH; area 15cm diameter resolved by 14AUG91 PM; Noted local rxn only w/o systemic or neurological damage;
After his flu shot on 11/13, he was being driven home by his brother and he started seizing. He was shaking and unresponsive and urinated in the car seat. Brother pulled the car over and shook patient who came around. He was very tired afterward, and did not remember the event. He also had a seizure after a series of immunizations as a young child, but not sure which shot caused it that time. Mom thinks flu vaccine was one of the shots given that day. We will no longer give him flu shots.
2 hours after vaccination had pain shooting from injection site up the neck. Arm was also sensitive to touch, but not sensitive to movement.  Upper right arm was warm and red with rash that was larger than just localized to injection site.. Two days after injection, came to pharmacy was advised to seek medical attention. was prescribed Prednisone 10mg 1-2 qd for 7 days.
Had rashes on my upper body; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of RASH (Had rashes on my upper body) in a 40-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 22-Apr-2021, the patient experienced RASH (Had rashes on my upper body). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (ANTIHISTAMINE ALLERGY RELIEF) for Rash, at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Rash, at an unspecified dose and frequency. On 24-Apr-2021, RASH (Had rashes on my upper body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
pain and swelling at injection site which extended into arm and neck associated with paresthesias, resolved low grade left hemicranial daily headache, persistent since vaccine bilateral blepharospam, intermittent bilateral tinnitus intermittent, worse on left side bilateral eye irritation, persistent pain with certain movements of right arm, persistent
Head ache,  unable to concentrate, Blurred vision,  cannot focus double vision. Started approx. 4 hours after the injection and is still an issue 7 days later.
expired dose; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (expired dose) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031B21A, 020M21A and LOT 027A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 24-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Sep-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (expired dose). At the time of the report, EXPIRED PRODUCT ADMINISTERED (expired dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   No treatment information was provided.
Patient received her 3rd GARDASIL/HPV vaccination on 6/02/08.  She was seen in the ER on 6/21/08 with diagnosis of Erythema Nodosum.  ? related to vaccination. 9/10/08-records received for DOS 6/21/08-presentd to ED with C/O migraine and rash. DX:erythema nodosum. Physical exam on 11/27/07 C/O right anterior knee pain. 7/23/08 persistent knee pain waxing and waning lower leg rash/lumps with sensitivity. After third dose of HPV C/O stiff neck on right side, severe headache, nausea and dizziness which lasted for about 3 days.
high indicators for Rheumatoid Arthritis; This is a spontaneous report from a non-contactable nurse (patient). A 44-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: ER8733), dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 (at the age of 44years) as single dose for Covid-19 immunization. The patient received the first dose of BNT162B2 (lot number: ER8733) on 05Mar2021 12:00 PM (at the age of 44years) via an unspecified route of administration (right arm) for Covid-19 immunization and developed severe pain in right shoulder approximately 7 days after 1st vaccine, went to ER and diagnosed with bursitis; also developed joint pain in hands, knuckles, toe joints in both feet, ankle joint pain in both feet. The patient is not pregnant at the time of vaccination. The patient's medical history was not reported. There were no concomitant medications. The patient was not diagnosed with COVID-19 prior to vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. It was reported that the joint pain in hands, knuckles, toe joints in both feet, ankle joint pain in both feet that developed 1-2 weeks after 1st vaccine has progressed and joint pain worsened over the next weeks. It was further reported that the shoulder joints began with pain. The patient had blood work done last week (unspecified date in 2021) and she have high indicators for rheumatoid arthritis. The adverse event resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care. The patient was treated with unspecified medications. The patient has not been tested for COVID-19 since the vaccination. The outcome of event was not recovered.  No follow-up attempts are possible. No further information is expected. Information on lot number already obtained.; Sender's Comments: Based on the available information, the known safety profile and the temporal association of BNT162B2 administration to the event, a possible contribution of the drug to the event cannot be excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review appropriate action in response, will be promptly notified to Committees, and Investigators, as appropriate and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any as any appropriate action in response, will be promptly notified to Committees, and Investigators, as appropriate.
Immediately when needle (vaccination) was removed from my arm, blood began gushing out. Bleeding eventually stopped, but severe bruising. Lasted 6 wks; pain at injection site continues 5 mos. later; also periodic numbness, tingling, weakness in arm continues, also joint pain.